β-hCG vaccine

Product Overview

Alternative Name: β-human chorionic gonadotropin

Development Status: Active Development

Target: Female

Mode: Non-hormonal

Delivery Type: TBD

Duration Type: Long-acting

Description: β-human chorionic gonadotropin (β-hCG) is a candidate immunogens to develop immunocontraceptive vaccine for human application.

Updated date: May 30, 2018

Vertical Tabs

Status

Project Phase: Late Development

Project Stage: Phase II

Status Details:
  • Phase II trials were completed in 1994. After a phase of inactivity, work began on a recombinant vaccine, which could be amenable to industrial production. Preclinical work on the reconfigured vaccine has been undertaken and there are plans to restart clinical trials.

Download Product Report